欧宝体育app网页版下载

Development Trajectory

▪     Development Trajectory

ClinPlus can fulfil the needs of domestic innovative pharmaceutical companies and improve the efficiency of clinical research by merging into the development trend of the SMO industry in China.

In 2009, our core management team started SMO.

In 2015, during the NMPA "722 inspection", ClinPlus received 0 project withdrawal.

In 2016, as the only SMO in Mainland China, ClinPlus was selected into the Asia-Pacific Clinical Trial Alliance.

In 2018, the first PD-1 project, awarded to ClinPlus, was approved to be sold in the market: BMS-Lung Cancer-Navumab;The first hyperlipidemia monoclonal antibody in China was approved to be sold in the market the assistance from ClinPlus: Amgen Bio-Hyperlipidemia-Ruibaian

In 2019, the first direct oral anti-hepatitis C virus drug in China was approved to be sold in the market with the assistance from ClinPlus; The world's first biologics for treating systemic lupus erythematosus (SLE) was approved to be sold in the market the assistance from ClinPlus; The first domestic human papillomavirus (HPV) vaccine in China was brought into the market the assistance from ClinPlus.

In 2020, ClinPlus was awarded "Shanghai Science and Technology Little Giant (including cultivation)".

In 2021, ClinPlus was awarded the title "The Star of Zhangjiang".

In 2022, ClinPlus was awarded the title "2021 Shanghai ZhuanJinTeXin.

ClinPlus has assisted the approval of over 90 drugs to be sold domestically and worldwide.